European Innovation Council

Catalogue
MEDICA 2024

11 - 14 November 2024

Düsseldorf, Germany

#EUeic
@EUeic
eic.ec.europa.eu


European
Innovation
Council
tanaza
The cloud-native platform
that empowers MSPs and ISPs
to deliver managed B2B Wi-Fi
JADBio
Accelerating
Drug Discovery
galgus
SEQUENTIA
Integrating microbiome data
into clinical practice
seluxit
Learn to save energy
with Seluxit
scantrust
tanaza
www.tanaza.com

Contents

1 What is the European Innovation Council?

The European Innovation Council (EIC) is Europe's flagship innovation programme to identify, develop and scale up breakthrough technologies and game changing innovations. The EIC has a budget of €10.1 billion to support innovation throughout the whole lifecycle, from early-stage research to proof of concept, technology transfer and the financing and scale up of startups and small companies.

The EIC functions under the following schemes:

- EIC Pathfinder supports research teams to research and/or develop emerging breakthrough technology.
- EIC Transition supports the maturation of a novel technology and development of a business case to bring it to market.
- EIC Accelerator supports funding and investments through the EIC Fund for individual startups and small companies to develop and scale up their breakthrough innovations.
- EIC Fund provides equity finance to startups and scaleups and it has a pro-active approach to co-investing with other investors offering a pipeline of attractive opportunities.

EIC support goes however far beyond funding. It provides to the EIC top-notch innovators with access to a range of high quality tailor-made Business Acceleration Services (EIC BAS) helping thus the scaling up and commercialisation of the EIC innovations.

EIC Delegation to MEDICA 2024:

Andreas Lymberis
Head of Sector
European Innovation Council
andreas.lymberis@ec.europa.eu

Gisela Santos
Project Advisor
European Innovation Council
gisela.santos@ec.europa.eu

2 EIC International Trade Fairs (ITF) Programme 3.0

Building on the experience of OTF 1.0 and 2.0, this EIC BAS programme aims to support EIC beneficiaries in their commercialisation strategy in European and foreign markets; it opens business avenues through participation in renowned trade fairs in the EU, the Middle East and the United States of America (USA), putting EU innovation in the spotlight in some of the most promising markets of the world.

The EIC ITF 3.0 will attend trade fairs in 3 different regions:

United States

Europe

Middle East

The trade fairs will cover the following sectors:

New Technologies / Industrial Technology

Health & Medical Care

Biotech & Pharma

Cleantech / Environment & Energy

3 Meet the EIC awardees exhibiting at MEDICA 2024

EIC International Trade Fairs (ITF) Programme 3.0

AkknaTek

Axelera AI

BrainCapture

Check Point Care

Dermagnostix

GlucoSet

GO-Pen

Interlinked

METAFORA

MYSPHERA

PhosPrint

Plas-Free

POROUS

SEQUENTIA

Time is Brain

EIC Tech to Market Entrepreneurship & Venture Building Programme

Modulux3D

PhysioMRI

PROMETHENZ

European Innovation Council

4 Find the EIC awardees at the EIC Pavilion

Messe Düsseldorf
Hall 14 | Stand 14A70



European Innovation Council

AkknaTek

Booth 1 | AkknaTek GmbH | EIC Pavilion | Germany | Established in 2017
www.akknatek.com

Dr. Edgar Janunts
CEO
edgar.janunts@akknatek.com

Mane Sahakyan
Sales & Marketing Manager
mane.sahakyan@akknatek.com

AkknaTek sets a new standard in cataract surgery.

AkknaTek is ISO-13485 certified medtech company based in Germany and specialised in Ophthalmology. We develop innovative imaging solutions for eye surgeons to improve the quality of treatment for eye diseases.

Company's main achievements/credentials

- ISO 13485 certified
- CE approved
- IP protected
- Award from the government of Germany on innovative technologies.
- International innovation awards
- Co-founded by the EIC Accelerator

Solutions featuring at MEDICA 2024

- With the Lens Reviewer, AkknaTek sets a new standard in cataract surgery, combining cutting-edge innovation, which has a potential to reshape the market and increase the technologically advanced lens implantations.
- Our technology empowers surgeons with unparalleled accuracy and confidence, reducing the need for follow-up procedures and leading to better visual outcomes, to address the most pressing needs of ophthalmologists and their patients.
- For the insurance companies and healthcare providers, it is an essential improvement of the quality of the treatment, while reducing the healthcare costs.

Target Business Partners

- Medtech investors
- Potential business partners
- Ophthalmologists
- Eye clinics
- Healthcare insurance providers
- Ophthalmological companies



AXELERA ARTIFICIAL INTELLIGENCE

Axelera AI

Booth 2 | Axelera AI BV | European Pavilion | The Netherlands | Established in 2021
www.axelera.ai

Flavio Devidé
Vice President - Sales & Customer Success
flavio.devide@axelera.ai

Bram Verhoef
Director of Customer Engineering & Success
bram.verhoef@axelera.ai

Simplifying & Accelerating AI.

Axelera AI is delivering the world's most powerful and advanced solutions for AI at the Edge. Our Metis™ AI platform, an integrated hardware and software solution, redefines AI inference at the edge, making computer vision applications more powerful, accessible, and user-friendly.

Company's main achievements/credentials

- CRN has acknowledged Axelera AI as one of the leading players in Edge AI solutions, standing alongside industry leaders like AMD, Intel Corporation, and NVIDIA.
- Selected for the Tech Tour Growth50 Europe List 2024.
- Named as CES 2024 Innovation Awards Honoree.
- Deloitte's Rising Star Award.
- Axelera AI has been recognised as one of Europe's top 100 deep tech startups and scaleups to watch in 2023, according to Sifted's recently released Global Startup Ecosystem Report 2023.

Solution featuring at MEDICA 2024

Our industry-defining Metis™ AI platform – a complete hardware and software solution for AI inference at the edge – makes computer vision applications more accessible, powerful and user friendly than ever before. We will be showcasing the utility on biomedical image segmentation such as tumor detection, where it helps improve accuracy and efficiency in healthcare-related tasks.

Target Business Partners

- Potential investors
- Distributors
- Customers

European Innovation Council

BrainCapture

Booth 3 | Braincapture APS | EIC Pavilion | Denmark | Established in 2019
braincapture.dk

Tue Lehn-Schiøler
CEO
tls@braincapture.dk

Palle Pedersen
Head of Sales, Europe
prp@braincapture.dk

The global point-of-care EEG device.

BrainCapture is a Danish medical technology company dedicated to bringing quality EEG to the 4+ billion who lack access to consistent neurological care. We use the tools of the 21st century - smartphones, connectivity and automation - to improve diagnosis and patient outcomes.



Company's main achievements/credentials

- CE mark (Class IIa).
- ISO13485 certified.
- Epilepsy Foundation - Shark Tank award winner - innovation in epilepsy treatment.
- Feature in "WHO Compendium of Innovative Health Technologies for Low-Resource Settings 2024".

Solutions featuring at MEDICA 2024

- BC-1 is a unique combination of hardware (portable, battery powered amplifier and cap), software (proprietary smartphone app that guides non-experts to record EEG), and telemedicine (GDPR-compliant cloud storage solution).
- BC-1 possesses several unique advantages over traditional EEG. It is deployable in any medical setting. Any healthcare worker can collect medical-grade EEG recordings. Its cloud storage connects patients remotely with EEG experts. And it is available at a highly competitive price compared to traditional EEG machines.

Target Business Partners

- Potential investors
- Distributors
- Public procurers
- Private procurers
- Customers



European Innovation Council

CHECK POINT CARE

Checkpoint Care

Booth 4 | Checkpoint Care LLC | EIC Pavilion | Bulgaria | Established in 2014
www.checkpoint.care

Boris Dimitrov
CEO
b.dimitrov@checkpointcardio.com

Kaja Vidic
Chief Business Development Officer
kaja.vidic@checkpointcardio.com

Advancing remote patient care.

Checkpoint Care transforms traditional healthcare by combining AI-powered telemedicine with advanced wearables. Solution enables continuous, personalised monitoring from hospital to home, solving the critical need for early detection and prevention, resulting in superior patient care.

Company's main achievements/credentials

- UN Global Champion Award 2023 for Health and Wellbeing in the World Summit Awards (WSA) competition.
- CE Medical Certifications ensuring compliance with EU regulations for medical devices.
- ISO 13485 Certification for quality management systems in medical devices.
- Cybersecurity Certifications safeguarding patient data and system integrity.
- EIC Accelerator Funding and National Innovation Award 2017 for innovative telemedicine solutions.
- Nightingale PCP Finalist in a highly competitive EU Pre-Commercial Procurement programme, lead by leading University Hospitals in EU.

Solution featuring at MEDICA 2024

Checkpoint Care's solution combines wearable devices, AI-driven analytics, and a 24/7 Virtual Care Center to deliver continuous, real-time patient monitoring. By integrating over 19 vital parameters and leveraging Digital Twin technology, we act as early detection and prevention decision support tool, for personalised care, reducing hospital admissions, reducing hospital stay, resulting in better patient outcomes.

Target Business Partners

- Potential investors
- Public procurers
- Private procurers
- Distributors
- Customers

European Innovation Council

DERMAGNOSTIX

Dermagnostix

Booth 5 | Dermagnostix GmbH | EIC Pavilion | Germany | Established in 2021
www.dermagnostix.com

Natalie Garzorz-Stark
CEO
n.garzorz-stark@dermagnostix.com

Franziska Striebel
Team Lead Marketing
f.striebel@dermagnostix.com

Precision Dermatology Powered by Molecular Diagnostics.

Dermagnostix is a university specialty diagnostics spin-off founded in 2021. Dermagnostix develops and commercialises novel molecular diagnostic tests for unmet clinical needs in dermatology to increase the accuracy of skin diseases diagnoses and to support clinicians in the prescription of the most suitable therapeutics.

Company's main achievements/credentials

- First centrifugal microfluidics platform technology for sample-to-answer solutions of complex molecular workflows.
- ISO 13485 certified.
- Product suite launched: PsorX-LabDisk CE-IVD, CE-IVD LabDisk-Analyzer Platform, Connectivity Solution. For more information, please see the official press release.
- Country launch in Germany & Czech Republic.
- Fully automated production line of LabDisks at economies of scale with shareholder Hahn-Schickard.
- Strong IP and exclusive licensing (>25 patents).

Solution featuring at MEDICA 2024

PsorX-LabDisk is the first molecular test for the differential diagnosis of psoriasis and eczema - two inflammatory skin diseases that pose a diagnostic challenge due to phenotypic overlap. Each LabDisk contains all reagents required for the analysis and is processed fully automated in the LabDisk-Analyzer in only two hours. The workflow is simple and intuitive: load the LabDisk with an FFPE tissue sample, close the input slot, insert the LabDisk into the LabDisk-Analyzer and start the analysis.

Target Business Partners

- Potential investors
- Strategic partners, e.g. large laboratories, CROs, larger diagnostic companies
- Distributors for Europe and beyond

GlucoSet
INTENSIVE CARE MONITORING

GlucoSet

Booth 6 | GlucoSet AS | EIC Pavilion | Norway | Established in 2012
www.glucoset.com

Lukas Scherer
CTO - Chief Technological Officer
lukas.scherer@glucoset.com

Igor Stankowski
Engineering Support for Medical Devices
igor.stankowski@glucoset.com

Improving ICU decision making by supporting insulin therapy.

Insulin therapy is a life-or-death problem in >80% of ICU patients, now solved with repeated manual blood samples and cumbersome dosing protocols. This €1.7B market craves disruption. GlucoSet's device helps ICUs slash nurses' workload by 20%, infection risk by 40% and mortality by 25%.

Company's main achievements/credentials

- Winner at the Diabetes Center Berne Open Innovation Challenge 2021 for best diabetes product.
- First-in-human completed and feasibility proven.
- Patents granted & high barrier of entry for competitors.
- Experienced medtech lead investor secured, leading the first closing.
- Medical device in series A round with strong lead investor, first 30 patient test planned Q4 2024.

Solution featuring at MEDICA 2024

GlucoSet ICU Monitoring System is uniquely real-time, minimally invasive (sensor on finger) and integrates seamlessly with existing ICU processes.



Target Business Partners

- Potential investors
- Hospital procurement
- Hospital clinical for potential clinical research collaboration
- Distributors
- M&A deals: Medication Pumps, Patient monitor, Nutrition

European Innovation Council

GO-PEN
Affordable insulin pen for all

GO-Pen

Booth 7 | GO-Pen APS | EIC Pavilion | Denmark | Established in 2019
www.go-pen.com

Ole Nielsen
CEO
ole@go-pen.com

Amin Zayani
Director of Product Management
amin@go-pen.com

Affordable insulin pen for all.

GO-Pen makes an insulin pen affordable for all. In diabetes one of the biggest innovations the last 50 years is the insulin pen. Still 1 out of 3 or 20 million people, mostly resource poor, is still injecting insulin with syringes mostly causing avoidable long term health issues

Company's main achievements/credentials

- Management system is ISO 13485 certified.
- FDA submission for clerance.
- CE mark full file submission for clearance.
- Winner American Diabetes Association 2023 innovation contest (Price: Marketina and communication).
- Winner Diabetes Center Bern Innovation (Price. EUR 100K).
- Winner Sportsgoodfonden innovation price (EUR 20K).
- Winner European innovation council acceleration price (EUR 2.5m).
- Winner European Innovation council seal of excelence.
- Winner UK innovate innovation price.



Solution featuring at MEDICA 2024

GO-Pen® is more for the same. Users will pay what they are used to with syringes but get a modern insulin pen.



Target Business Partners

- Potential investors
- Distributors
- Public procurers
- Private procurers

Interlinked

Booth 8 | Interlinked AB | EIC Pavilion | Sweden | Established in 2016
www.interlinked.care

Katarina Hedbeck
CEO
katarina.hedbeck@interlinked.care

Puneet Gaharana
Chief Strategy Officer
puneet.gaharana@interlinked.care

ReLink: Enhancing safety in IV therapy & nephrostomy drains.

Interlinked is a Swedish MedTech company dedicated to making medical tubes safer and smarter with ReLink, its innovative breakaway connector technology. ReLink reduces catheter dislodgement and enhances safety for patients and nurses. Now seeking distribution partners.

Company's main achievements/credentials

- Successful EU clinical trial showing a 73% reduction in peripheral IV catheter dislodgement incidents.
- CE marked for IV therapy and nephrostomy drains; FDA registered for nephrostomy drains.
- 1000+ ReLink devices used on patients.
- Patents in 25+ markets including EU, US, Japan, China and India.

Solution featuring at MEDICA 2024

ReLink (known as LinkUS in the US) is a breakaway connector technology featuring double-sided, self-sealing valves, and weak-link activation to protect catheter placement sites. By minimising the risk of dislodgement, ReLink elevates patient and nurse safety, prevents fluid spillage and loss, enhances treatment stability, and saves valuable nursing hours.

Target Business Partners

- Potential investors
- Distributors
- Public procurers
- Private procurers
- Customers

European Innovation Council

METAFORA

Vincent Petit
CEO
vincent.petit@metafora-biosystems.com

METAFORA

Booth 9 | METAFORA Biosystems SAS | EIC Pavilion | France | Established in 2011
www.metafora-biosystems.com

Kamila Czechowska
Chief of Diagnostic Product Development Officer
kamila.czechowska@metafora-biosystems.com

METAflow, unlock the power of single cell data analysis.

Data analysis is a critical bottleneck in single cell technologies. METAFORA is a medtech developing METAflow, a highly differentiating cloud-based software, leveraging AI seamlessly to help users achieve better robustness and cost-efficiency.

Company's main achievements/credentials

METAflow By METAFORA

- METAflow RUO version is launched and shows good traction from scientists in basic and clinical research.
- The clinical grade solution is compliant with CFR Part 11 regulation, and shall be CE-IVD mark by Q4 2024. METAflow is the first general purpose AI-powered cytometry data analysis solution on the market.
- METAFORA is ISO 13485:2016 certified, and is laureate of multiple awards such as the EIC Accelerator and H2020 programmes from the European Commission.

Solution featuring at MEDICA 2024

METAflow is an AI-powered single cell data analysis platform supporting applications, for life sciences and clinical diagnostics. Our team of biologists and mathematicians built a solution with unmatched robustness. In a nutshell, METAflow provides objective, 100% reproducible, traceable results, reducing by 80% time to result, all in a collaborative digital platform.
METAflow marks a dramatic advance over existing solutions regardless of data processing skills.



Target Business Partners

- Potential investors
- Distributors
- Customers such as Clinical Research Organisations

MYSPHERA

MYSPHERA

Booth 10 | MYSPHERA SL | EIC Pavilion | Spain | Established in 2012
www.mysphera.com

Salvador-Enrique Vera Manero
CEO
svera@mysphera.com

Daniel Vera
CMO
dvera@mysphera.com

Save time. Improve Care.

At MYSPHERA we put our expertise at the service of technology and people to automate, simplify and speed up the most complex processes of a healthcare organisation. Our goal is to free up health professionals from spending their time on anything but patient care. We offer a product that can increase the number of surgeries performed in your hospital by 16%, significantly improve staff coordination, and deliver an ROI of over 700%.

Company's main achievements/credentials

- RFID Journal Award: Best IoT platform in the world.
- Best European Healthcare Design Award.
- Best Success Case in Value Based Healthcare Awards.

Solution featuring at MEDICA 2024

MYSPHERA's RTLS workflow automation:

1. An agile and automated patient flow. Patients change their status in the process through movement and the accomplishment of certain events. We automatically generate tasks to minimise idle time and facilitate coordination.
2. The information you need, when you need it. A hospital is a moving environment. The relevant information for each moment of the process is accessible and available to everyone.

Target Business Partners

- Distributors
- Customers (hospitals)

European Innovation Council

PhosPrint
Advanced Technologies

Ioanna Zergioti
CEO
zergioti.ioanna@phosprint.eu

PhosPrint

Booth 11 | PhosPrint PC | EIC Pavilion | Greece | Established in 2019
www.phosprint.eu

Apostolos Klinakis
Clinical Director
klinakis.apostolos@phosprint.eu

First in-vivo bioprinting tool for tissue repairing.

Phosprint was founded in 2019 and is a spinoff from the National Technical University of Athens. We develop laser bioprinting systems for ex vivo and in vivo use and specialised protocols for cell isolation, expansion and printing for regenerative medicine applications.

Company's main achievements/credentials

- EU Commission's Seal of Excellence for our proposal submitted under the Horizon 2020's SME instrument phase (2019).
- Bodossaki Foundation Grant for funding of IP costs.
- POC award Patras Science Park (2021).
- 3rd Prize Startup Challenge competition, SPIE Photonics West Congress SF (2023).
- EIC Accelerator Grant First Award (project 190195672): Laser bioprinting device and in vivo applications (2023).
- StartSmart SEE Accelerator Spring 2024 Edition: Start-Up Pitch Competition Winner (2024).

Solution featuring at MEDICA 2024

Laser printing of autologous urothelial cells, previously isolated and expanded from healthy biopsy of the patient, onto de-epithelised intestinal tissue. Process occurs in the OR as an alternative to the classic enterocystoplasty or orthotopic neobladder surgery relieved from side-effects. Printer engineers hybrid tissue, made of the intestinal muscle layer and urothelial layers developed by patient's own healthy intestine and urothelial tissues and be used as orthotopic neobladder.

Target Business Partners

- Investors: Venture Capital, Corporate VC and Angel investor funds
- Large vendors and manufacturers: major MedTech companies
- Sourcing suppliers: major MedTech HW and consumables suppliers

European Innovation Council

PlasFree

Plas-Free

Booth 12 | Plas-Free LTD | EIC Pavilion | Israel | Established in 2017
www.plas-free.com

Zeev Dvashi
CEO
zeev@plas-free.com

Dan Aridor
CMO
dan@plas-free.com

Enhancing Coagulation, Saving Lives Reducing Costs.

ClearPlasma, an innovative plasma filtration system that improves the coagulation properties of plasma units designated for transfusion.
The ClearPlasma device extracts plasminogen, an important protein responsible for dissolving blood clots. By absorbing the plasminogen from the plasma units, ClearPlasma enhances coagulation and promotes hemostasis in the bleeding patients.

Company's main achievements/credentials

- The ClearPlasma device has been tested successfully on 56 Upper Gastrointestinal bleeding (UGIB) patients in a multicentral, double-blind, randomized, controlled clinical study done in Europe and Israel. The use of ClearPlasma reduced the mortality events to zero (0) compared to 2 deaths that were reported in the control group.
- More than 700 ClearPlasma devices were successfully used on patients in 3 different clinical trails with.
- Plas-Free is ISO13485 certified, and is laurate of multiple awards. First place in the ENRICH Funding Summit, second Place in the MedTech Startup Contest, and more.
- All Plas-Free patents are granted in US, Europe and additional territories.
- ClearPlasma is expected to be approved by Q1/2025

Solution featuring at MEDICA 2024

ClearPlasma is a single-use device that improves treatment for patients with massive bleeding by stabilizing clot formation, reducing blood loss, preserving hemoglobin levels, and minimizing the occurrence of re-bleeding events.
In addition, ClearPlasma has been shown to reduce hospitalization duration by more than 17%. This innovative device has proven to be a new and effective modality to reduce blood loss and has the potential to transform the treatment of patients experiencing massive bleeding.

Target Business Partners

- Investors
- Business partners
- Distributors
- Customers: Healthcare Providers and Blood Establishments



Figure 2. ClearPlasma device and its components - as provided to the user:
(1) Inlet Cap, (2) Body, (3) Outlet Cap, (4) Inlet Connecting Line, (5) Outlet Connecting Line, (6) Silicone Plug



European Innovation Council

POROUS
Cortical Bone Microstructure Analysis

POROUS

Booth 13 | POROUS GmbH | EIC Pavilion | Germany | Established in 2021
www.porous.care

Julia Eschenbrenner
CEO
eschenbrenner@porous.care

Jonas Massmann
Chief Technology Officer
massmann@porous.care

NextGen Ultrasound for Cortical Bone Microstructure Analysis.

POROUS offers a unique 3D ultrasound solution for cortical bone microstructure parameters. Our mission is the early and accurate diagnosis of osteoporosis to allow for timely interventions to prevent fractures, to empower women's and men's bone health & healthy aging.

Company's main achievements/credentials

- ISO 13485 certified.
- EIC accelerator grant recipient.
- Winner of Innovation Award Berlin-Brandenburg 2023.
- Charité Universitätsmedizin Berlin Spin-off.

Solutions featuring at MEDICA 2024

POROUS ultrasound device features dedicated software for assessing cortical bone microstructure, providing clinical researchers with a novel tool to study metabolic bone disorders ranging from widespread osteoporosis to rare bone diseases. It enables low-cost, non-radiation measurement of dynamic biomarkers and validates early and accurate diagnosis of osteoporosis.

Target Business Partners

- Potential investors focusing on Series A, medtech, womens' health, healthy aging
- Customers in bone health research (academia, pharma & health nutrition industry)
- Business partners: ultrasound companies, ultrasound OEM manufacturers, ISO13485 manufacturers with productions in small quantities (Berlin/Brandenburg region) and medtech device distributors for Europe, UK, Japan, Hongkong, China, USA

European Innovation Council

SEQUENTIA
DECODE • DISCOVER • DISRUPT

SEQUENTIA

Booth 14 | Sequentia Biotech SL | EIC Pavilion | Spain | Established in 2013
www.sequentiabiotech.com

Walter Sanseverino
CEO
wsanseverino@sequentiabiotech.com

Tiago Machado
CMO
tmachado@sequentiabiotech.com

Sequentia powers omics innovation in biomedicine

Omics sciences have revolutionised biomedicine, addressing critical global challenges. SEQUENTIA delivers advanced bioinformatics tools to manage and analyse omics data, turning complex information into actionable insights for diagnostics, therapeutics, and research applications.

Company's main achievements/credentials

- Successfully completed over 800 bioinformatics projects, served clients in 63 countries - including MNEs, top research institutions, hospitals and public authorities and contributed to over 70 publications with a H-index of 130.
- SEQUENTIA has been awarded over 10 international competitive grants and awards for its cutting edge technology, including the EIC Accelerator; the company implements ISO 13485 and GDPR standards.

Solution featuring at MEDICA 2024

Advanced consulting services to address the most complex omics data analysis needs and accelerate diagnostics, therapeutics and clinical research applications.

Our solution supports clients from samples to breakthrough discoveries , including samples sequencing, bioinformatics analysis and data integration, tailored reporting, expert bioinformatics assessment, post service support and project management, all in a cost effective manner.

Target Business Partners

- Distributors
- Public procurers
- Private procurers
- Corporate and public customers

European Innovation Council

timeisbrain

Time is Brain

Booth 15 | Time Is Brain SL | EIC Pavilion | Spain | Established in 2020
www.tibtimeisbrain.com

Blas Dias
COO
blasdc@tibtimeisbrain.com

Antonio Martinez
CMO
amartinez@tibtimeisbrain.com

We have created BraiN20®, the stroke ECG.

Time is Brain (TiB) is an innovative technology-driven startup born from the visionary minds of leading neurologists. In 2013, they started a groundbreaking research that led to BraiN20®, the only medical device capable of real-time brain monitoring for acute stroke patients.



Company's main achievements/credentials

- TiB founders have discovered, patented, and validated the signal N20 as a novel biomarker of brain viability in more than 200 stroke patients (PROMISE trial).
- BraiN20® functional prototype was developed and validated in a relevant environment (TRL 7).
- BraiN20® tech transfer to production and manufacturing of a short series has been completed.
- TiB has been fundraised with>8M€ between grants and equity, from public funds and private investors. The European Innovation Council (EIC) supported our company with a 2.5M€ grant and 3.3M€ equity.
- Our company was awarded with the first price of the Medlim and EIT Health Catapult programmes (2022-2023).

Solution featuring at MEDICA 2024

BraiN20® is the stroke ECG: a portable, easy-to-use, and non-invasive medical device. It enables an AI-based analysis of the N20 signal, a novel, and patented biomarker of the brain viability discovered by TiB founders. For the first time, hospitals and emergency services can monitor in real-time the brain status from stroke onset and during the entire patient journey. BraiN20® enables a standardised, equal, and better health outcome for all acute stroke patients.

Target Business Partners

- Distributors

5 EIC Tech to Market Entrepreneurship & Venture Building Programme

The EIC Tech to Market programme empowers early-stage innovators to bridge the gap from research to market through two key components: Entrepreneurship and Venture Building.

- Entrepreneurship Programme: Tailored for deep-tech researchers, this component provides hands-on training, coaching, and expert guidance to turn breakthrough technologies into viable businesses. Participants refine their value propositions, strengthen business models, and develop market-ready solutions through practical support in pitching, business validation, and market alignment.
- Venture Building Programme: This component supports EIC beneficiaries in creating successful startups by leveraging their research. Through expert-led workshops, team-building support, and tailored venture services, innovators receive the tools and insights needed to build strong teams, validate business models, and confidently launch their ventures.

MODULUX3D

Modulux3D

Modulux3D | EIC Pavilion | Germany
b-brighter.eu

Levin Hafa
Co-founder and CSO
levin.hafa@modulux3d.com

Zeeshan Mahmood
Co-founder and VP of BD
zeeshan.mahmood@modulux3d.com

AI-driven 3D light bioprinters for the future of drug testing

Modulux3D (B-Brighter project) is an innovative project focused on revolutionising preclinical testing in the pharmaceutical industry through advanced laser-based 3D-Bioprinting technology. Our solution enables the creation of highly precise human tissue models that better mimic human physiology, improving the accuracy and reliability of drug development while significantly reducing the need for animal testing.

At Modulux3D, we offer a cutting-edge bioprinting platform that combines advanced printing technology with real-time microscopy to produce complex, customisable tissue structures. These models are particularly beneficial for oncology research, providing faster, more reliable results and helping pharmaceutical companies develop more effective treatments.

We are attending MEDICA to connect with potential partners and customers, showcasing how our technology can address the growing demand for more ethical and efficient preclinical testing. Our goal is to explore collaborations that will help bring Modulux3D to market and contribute to the future of drug development.

Physio MRI

Physio MRI Tech SL | EIC Pavilion | Spain
www.physiomri.com

Alfonso Ríos Alonso
CEO
alfonso.rios@physiomri.com

Jonatan Demian Fatelevich
CSO
jon@physiomri.com

The first portable device revolutionising the world of extremity imaging.

Our NextMRI project offers a portable, low-field MRI scanner, enabling MRI imaging beyond traditional medical settings, including remote areas and home healthcare. We have successfully demonstrated its use in diverse real-world environments, such as at a patient's home and a major sporting event.

There is no longer a need to compromise quality for portability and accessibility. Our MRI machine has it all: portability, user-friendliness, unmatched image quality, and advanced technology that opens up new possibilities in healthcare.

At MEDICA 2024, we aim to showcase how this technology can revolutionise accessible diagnostic imaging.

PROMETHENZ

advancing cancer nanotherapeutics

PROMETHENZ

PROMETHENZ | EIC Pavilion | Spain
https://www.hotzymes.eu/

Dr. Lorena Betancor
Founder/CEO
betancor@ort.edu.uy

Dr. Valeria Grazú
Founder/CSO
vgrazu@unizar.es

Redesigning biocatalysis with a new generation of magnetic bioreactors.

PROMETHENZ (Hotzymes project) is a spatio-temporally activable nanoplatform capable of generating chemotherapeutics at the tumor site for a desired duration to enhance chemotherapy effectiveness and avoid its short and long-term side effects. The key to PROMETHENZ technology lies in its remote activation ability through an alternate magnetic field that triggers the therapy by increasing the temperature generated within hybrid nanoparticles. This local temperature rise activates an enzyme that converts the administered prodrug into an antitumoral drug directly at the tumor site.

Our technology is based on years of research by a Uruguayan and Spanish scientific consortium and has been validated in in vivo studies in mice. Although applicable to any solid tumor, our initial product is focused on treating pancreatic cancer, the fourth leading cause of cancer deaths globally. It is one of the deadliest cancers, with a 5-year survival rate of just 11% and rising mortality in both sexes. Only 15%–20% of patients present with resectable disease and it shows little sensitivity to traditional chemotherapy or even innovative therapies like immunotherapy or vectoried chemotherapy.

PROMETHENZ aims to shift chemotherapy from an adjuvant or palliative role to a central role in pancreatic cancer management, improving patient outcomes where current treatments are ineffective and cause significant side effects, impacting health and quality of life.

Attending MEDICA offers our startup the opportunity to connect with leading healthcare professionals, cutting-edge technology providers, and potential collaborators from around the world. We aim to showcase our technology, explore strategic partnerships, and stay at the forefront of medical advancements in the global market

European Innovation Council

EIC International Trade Fairs
Programme 3.0

Powered by EIC Business Acceleration Services

eic.ec.europa.eu